PFS
ZVRA icon

Prospera Financial Services’s Zevra Therapeutics ZVRA Stock Holding History

Prospera Financial Services’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,500
Closed -$53K – 2660
2022
Q1 		$53K Hold
10,500
– – ﹤0.01% 1360
2021
Q4 		$91K Buy
+10,500
New +$93.7K ﹤0.01% 851

Other funds holding ZVRA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Prospera Financial Services's ZVRA Position: Q2 2022 in Review

Prospera Financial Services sold out of Zevra Therapeutics (ZVRA) in Q2 2022, closing a stake of 10,500 shares — an estimated $53K sold.

Prospera Financial Services first reported a position in ZVRA in Q4 2021 and held it in 2 quarters. The position peaked at $91K in Q4 2021. 72 funds tracked by Wall St. Rank hold ZVRA as of Q2 2022.

  • Prospera Financial Services reported no remaining Zevra Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 10,500 Zevra Therapeutics shares in Q2 2022, an estimated $53K.
  • Prospera Financial Services first reported a position in Zevra Therapeutics in Q4 2021 and held it in 2 quarters.
  • Prospera Financial Services's Zevra Therapeutics position peaked at $91K in Q4 2021.
  • 72 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.